तुलना करने के लिए मीट्रिक्स | 461030 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध461030पीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −5.1x | −6.3x | −0.4x | |
PEG अनुपात | 25.33 | −0.13 | 0.00 | |
क़ीमत/बुक | 1.8x | 1.6x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 7.7x | 8.2x | 3.0x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 0.0% | 56.0% | |
उचित मूल्य अपसाइड | अनलॉक करें | 5.9% | 9.1% | अनलॉक करें |
IMB Dx, Inc. provides liquid biopsy platform in South Korea. It offers AlphaLiquid Platform that provides circulation-tumor DNA-based precision diagnostics solutions across various stages of cancer for patients, survivors, and individuals; AlphaLiquid HRR for diagnostics of targeted therapies, utilizing liquid biopsy profiling technology; and AlphaLiquid 100 test, a tool that enables the detection of biomarkers across 118 cancer-related genes through one blood test. The company also provides CancerDetect, a liquid biopsy platform for the early detection of cancer recurrence post-surgery; and CancerFind, a blood-based test for various cancer early detection. IMB Dx, Inc. was founded in 2018 and is based in Seoul, South Korea.